Monograph Details
|
|
Immune System
> Immunization
|
|
TWINRIX |
| Manufacturer |
|
GlaxoSmithKline Pharmaceuticals |
| Legal Classification |
|
Rx
|
| Generic Name |
|
Hepatitis A inactivated 720 ELISA Units (EL.U.), hepatitis B surface antigen (recombinant) 20 micrograms; per mL; susp for IM inj; aluminum adsorbed; contains trace amounts of thimerosal, formalin, neomycin, yeast protein. |
| Indications |
|
Hepatitis A and hepatitis B immunization. |
| Children |
|
<18 years: not recommended. |
| Adults |
|
≥18 years: 1 inj IM in deltoid area at 0-, 1-, and 6 months. Alternate 4-dose schedule: 1 inj IM in deltoid area at 0-, 7-, and 21 to 30-days followed by booster dose at month 12. |
| Precautions |
|
May defer in acute febrile illness or active infection. Bleeding disorders. Thrombocytopenia. Immunodeficiency: may get suboptimal response. Have epinephrine (1:1000) inj available. If given with immune globulin, use separate syringe and different site. Pregnancy (Cat.C). Nursing mothers. |
| Interactions |
|
Immunosuppressives may reduce efficacy. |
| Adverse Reactions |
|
Inj site reactions, headache, fatigue, GI upset, fever. |
| How Supplied |
Single-dose vials—1, 10
Single-dose prefilled syringes—5 |
| Additional Resources |
|
• Related Prescribing Note |
|
|
|
|
